Oxford Nanopore
Oxford Nanopore Technologies was founded in 2005 to develop an electronic, single molecule sensing system based on nanopore science. The company now has more than 250 employees from multiple disciplines including nanopore science, molecular biology and applications, informatics, engineering, electronics, manufacturing and commercialization. Oxford Nanopore's instruments — MinIon, PromethIon, and GridIon are adaptable for the analysis of DNA, RNA, proteins, small molecules and other types of molecule.
Oxford Nanopore Facts
Â
CEO: Gordon Sanghera
Website: www.nanoporetech.com
Ticker symbol: Privately held
Headquarters: Oxford, UK
Number of employees: 250+
In Brief This Week: PerkinElmer, OraSure Technologies, LabCorp, Molzym, UniLabs, and More
News items for the in vitro diagnostics industry for the week of May 10, 2021.
The project, being coordinated by UCSF and the University of Heidelberg, has a total budget of $20 million and is expected to run through 2025.
Oxford Nanopore SARS-CoV-2 Sequencing Test Gets CE Mark
Oxford Nanopore said it is rolling out the LamPore test globally, initially in the UK, Germany, Switzerland, and the United Arab Emirates.
Team Shows Diagnostic Potential for Oxford Nanopore SARS-CoV-2 Assay, Calls for Improvements
A clinical evaluation of LamPore, expected to be CE marked shortly, called it promising for high-throughput testing but recommended a more streamlined workflow.
Clear Labs Nanopore Sequencing Coronavirus Test Gets FDA Emergency Use Authorization
The nanopore sequencing-based test is designed to both diagnose SARS-CoV-2 infection, as well as monitor mutations that may affect efforts to combat the virus.